Forte’s main strengths are its clean balance sheet with no debt, a solid cash position relative to near‑term obligations, and a tightly focused R&D strategy built around a scientifically compelling mechanism. The company directs most spending into research rather than overhead, and early clinical signs in celiac disease lend credibility to its lead program. Operationally, the structure is simple and flexible, which can help the company pivot as data emerge.

Key risks center on the absence of revenue, ongoing large losses, and heavy reliance on equity financing to fund trials. Scientifically, the company is highly concentrated in a single asset and operates in competitive, scientifically complex disease areas where many larger players are active. Clinical, regulatory, and commercial uncertainties are substantial, and the negative history with its prior program underscores the inherent volatility of early‑stage biotech development.

The outlook for Forte is tightly linked to the clinical trajectory of FB‑102 over the next few years. Upcoming mid‑stage trial readouts in celiac disease and early‑stage results in vitiligo and alopecia areata will be pivotal in determining whether the mechanism can translate into a meaningful therapeutic profile. In the meantime, the company appears financially positioned to continue its current plans for a while but will likely need additional funding or partnerships as development advances. Overall, this remains an early, high‑uncertainty story where scientific and clinical outcomes will drive the financial narrative far more than current financial performance metrics.